TY - JOUR
T1 - Repeated-dose toxicity of HSP27-binding heptapeptide in mice
AU - Lee, Hae June
AU - Lee, Yun Sil
N1 - Funding Information:
This study was supported by a grant from the Korea Healthcare Technology R&D Project of the Ministry for Health, Welfare, and Family Affairs (A080997) and by a grant from the Nuclear Research and Development Program of the National Research Foundation of the Ministry for Education, Science, and Technology (grant code: M2AMA006) of the Korean government. The authors report no conflicts of interest. The authors alone are responsible for the content and writing of the paper.
PY - 2010/7
Y1 - 2010/7
N2 - Heptapeptide, including seven amino acids of the PKCδ V5 region, which can bind HSP27 and abrogate HSP27-mediated resistance against IR and cisplatin (Kim et al., 2007), was examined for single- and repeated-dose toxicity in mice. The single-dose experiment was performed with an intravenous and intraperitoneal injection of 100mg/kg of heptapeptide, and the repeated-dose experiment was 14 doses over 28 days at 0, 5, 25, and 100mg/kg of heptapeptide. Observations included clinical signs, mortality, body and organ weights, hematology, and serum biochemistry. No effects of heptapeptide on detected parameters were observed, and these findings indicated heptapeptide may be a possible therapeutic candidate without significant toxicity.
AB - Heptapeptide, including seven amino acids of the PKCδ V5 region, which can bind HSP27 and abrogate HSP27-mediated resistance against IR and cisplatin (Kim et al., 2007), was examined for single- and repeated-dose toxicity in mice. The single-dose experiment was performed with an intravenous and intraperitoneal injection of 100mg/kg of heptapeptide, and the repeated-dose experiment was 14 doses over 28 days at 0, 5, 25, and 100mg/kg of heptapeptide. Observations included clinical signs, mortality, body and organ weights, hematology, and serum biochemistry. No effects of heptapeptide on detected parameters were observed, and these findings indicated heptapeptide may be a possible therapeutic candidate without significant toxicity.
KW - Heptapeptide
KW - HSP27
KW - PCKδ
KW - Safety
KW - Toxicology
UR - http://www.scopus.com/inward/record.url?scp=77953269378&partnerID=8YFLogxK
U2 - 10.3109/01480540903483425
DO - 10.3109/01480540903483425
M3 - Article
C2 - 20429809
AN - SCOPUS:77953269378
SN - 0148-0545
VL - 33
SP - 284
EP - 290
JO - Drug and Chemical Toxicology
JF - Drug and Chemical Toxicology
IS - 3
ER -
